16.49
0.55%
+0.09
After Hours:
16.7694
0.2794
+1.69%
Catalyst Pharmaceuticals Inc stock is currently priced at $16.49, with a 24-hour trading volume of 1.10M.
It has seen a +0.55% increased in the last 24 hours and a +3.06% rose in the past month.
The chart indicates a potential bearish trend, as the stock is below the $16.52 pivot point. If it approaches the $16.23 support level, significant changes may occur.
Previous Close:
$16.40
Open:
$16.55
24h Volume:
1.10M
Market Cap:
$1.95B
Revenue:
$398.20M
Net Income/Loss:
$71.41M
P/E Ratio:
16.33
EPS:
1.01
Net Cash Flow:
$61.86M
1W Performance:
+3.45%
1M Performance:
+3.06%
6M Performance:
+19.41%
1Y Performance:
+31.60%
Catalyst Pharmaceuticals Inc Stock (CPRX) Company Profile
Name
Catalyst Pharmaceuticals Inc
Sector
Industry
Phone
305-420-3200
Address
355 Alhambra Circle, Suite 1250, Coral Gables
Catalyst Pharmaceuticals Inc Stock (CPRX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-21-23 | Initiated | Oppenheimer | Outperform |
Aug-24-22 | Downgrade | ROTH Capital | Buy → Neutral |
Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
Sep-07-18 | Resumed | Piper Jaffray | Overweight |
Oct-05-16 | Upgrade | Piper Jaffray | Neutral → Overweight |
Apr-26-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
Sep-30-14 | Reiterated | ROTH Capital | Buy |
Sep-16-14 | Reiterated | ROTH Capital | Buy |
Sep-15-14 | Reiterated | H.C. Wainwright | Buy |
Oct-21-13 | Reiterated | Aegis Capital | Buy |
Sep-24-13 | Initiated | Maxim Group | Buy |
Sep-06-13 | Reiterated | Aegis Capital | Buy |
Apr-18-13 | Initiated | Aegis Capital | Buy |
Aug-27-12 | Upgrade | Rodman & Renshaw | Mkt Perform → Mkt Outperform |
Oct-01-09 | Upgrade | Merriman | Sell → Neutral |
May-29-09 | Downgrade | Hapoalim | Neutral → Underperform |
May-29-09 | Downgrade | Merriman Curhan Ford | Buy → Sell |
Dec-15-08 | Initiated | Merriman Curhan Ford | Buy |
Nov-28-07 | Initiated | Rodman & Renshaw | Mkt Outperform |
Jan-31-07 | Initiated | Stifel Nicolaus | Buy |
Jan-05-07 | Initiated | First Albany | Buy |
View All
Catalyst Pharmaceuticals Inc Stock (CPRX) Latest News
Jump Financial LLC Has $1.08 Million Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - Defense World
Defense World
Catalyst Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
MarketWatch
Amalgamated Bank Reduces Stock Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - Defense World
Defense World
Catalyst Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
MarketWatch
Victory Capital Management Inc. Reduces Stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
MarketBeat
Victory Capital Management Inc. Decreases Stock Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - Defense World
Defense World
Catalyst Pharmaceuticals Inc Stock (CPRX) Financials Data
Catalyst Pharmaceuticals Inc (CPRX) Revenue 2024
CPRX reported a revenue (TTM) of $398.20 million for the quarter ending December 31, 2023, a +85.90% rise year-over-year.
Catalyst Pharmaceuticals Inc (CPRX) Net Income 2024
CPRX net income (TTM) was $71.41 million for the quarter ending December 31, 2023, a -14.05% decrease year-over-year.
Catalyst Pharmaceuticals Inc (CPRX) Cash Flow 2024
CPRX recorded a free cash flow (TTM) of $61.86 million for the quarter ending December 31, 2023, a -46.68% decrease year-over-year.
Catalyst Pharmaceuticals Inc (CPRX) Earnings per Share 2024
CPRX earnings per share (TTM) was $0.61 for the quarter ending December 31, 2023, a -17.57% decline year-over-year.
About Catalyst Pharmaceuticals Inc
Catalyst Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. Its product candidates include Firdapse, a proprietary form of amifampridine phosphate that has completed Phase III clinical trials for the treatment of patients with lambert-eaton myasthenic syndrome; is in Phase III clinical trial to treat congenital myasthenic syndromes; and is in Phase III clinical trial for the treatment of anti-MuSK antibody positive myasthenia gravis, as well as is in Phase II clinical trial for patients with spinal muscular atrophy type 3. The company is also developing CPP-115, a gamma-aminobutyric acid aminotransferase inhibitor for the treatment of refractory infantile spasms; and CPP-109, a vigabatrin tablet. It has license agreements with Northwestern University, New York University and the Feinstein Institute for Medical Research, and BioMarin Pharmaceutical Inc. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Cap:
|
Volume (24h):